ReviewCurrent oncology (Toronto, Ont.)2023
Mesenchymal Tumors of the Breast: Fibroblastic/Myofibroblastic Lesions and Other Lesions.
Review in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 14 citations in OpenAlex.
- A rare case report of solitary neurofibroma arising in the male breast.International journal of surgery case reports · 2026Article
- Article
- Haemangioma of the breast: The added value of contrast enhanced ultra-sound (CEUS) in the vascularity assessment of a rare mesenchymal lesion.Radiology case reports · 2025Article
- Imaging Features of the Mesenchymal Tumors of the Breast according to WHO Classification: A Pictorial Essay.Journal of the Korean Society of Radiology · 2025Review
- Article
- Dermatofibrosarcoma protuberans of the breast in pregnancy.Journal of surgical case reports · 2024Article
- Cavernous hemangioma of the breast: a case report.Annals of medicine and surgery (2012) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal breast tumors are a rare and diverse group of tumors that present some of the most challenging cases for multidisciplinary breast cancer teams. As a result of overlapping morphologies and a lack of large-scale studies on these tumors, practices are often heterogeneous and slow to evolve. Herein, we present a non-systematic review that focuses on progress, or lack thereof, in the field of mesenchymal breast tumors. We focus on tumors originating from fibroblastic/myofibroblastic cells and tumors originating from less common cellular origins (smooth muscle, neural tissue, adipose tissue, vascular tissue, etc.).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.